Omer Ersin Muz1, Kenan Dagdelen2, Tuncay Pirdal3, Mete Guler4. 1. Department of Ophthalmology, Eskisehir Yunus Emre State Hospital, Uluonder Mahallesi, 26190, Tepebasi, Eskisehir, Turkey. ersinmuz@gmail.com. 2. Department of Ophthalmology, Eskisehir Yunus Emre State Hospital, Uluonder Mahallesi, 26190, Tepebasi, Eskisehir, Turkey. 3. Department of Ophthalmology, Ordu State Hospital, Sahincili Mahallesi, Dr. Fahrettin Onsel Caddesi, 52200, Altınordu, Ordu, Turkey. 4. Department of Ophthalmology, School of Medicine, University of Kahramanmaras Sutcu Imam, Avsar Mahallesi Bati Cevreyolu Bulvari No: 251/A, 46000, Onikisubat, Kahramanmaras, Turkey.
Abstract
BACKGROUND: To compare the effect of two different prostaglandin analogues (Travatan® vs. Xalatan®) on ocular surface parameters. METHODS: This study includes 44 eyes of 44 patients with newly diagnosed primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Patients were randomly divided into two groups and treated with either benzalkonium chloride (BAK)-preserved latanoprost and polyquad-preserved travoprost. Changes in intraocular pressure (IOP) levels and ocular surface parameters including ocular surface disease index (OSDI) questionnaire, tear breakup time (TBUT), ocular surface staining scores, and Schirmer test scores of patients were performed at baseline, 1, 3, 6, and 12 months of treatment and compared. RESULTS: The age, sex ratio, visual acuity, central corneal thickness, and cup/disc ratio were similar between the groups. A decrease in IOP levels (23.3 ± 2.5 to 15.5 ± 2.3), TBUT (5.5 ± 2.3 to 4.1 ± 1.7 s), Schirmer test values (11.3 ± 5.9 to 8.6 ± 4.7 s), and a worsening in OSDI scores (44.6 ± 15.2 to 55.1 ± 13.1) and staining scores (1.7 ± 1.6 to 2.3 ± 1.8) were observed in all patients in the first month of treatment (p < 0.05, for all). No further worsening was detected during the 1-year follow-up. There was no difference between the groups in terms of alterations in IOP levels and ocular surface parameters. CONCLUSION: Travatan® and Xalatan® have a similar effect on IOP levels and ocular surface parameters in patients with POAG and OHT.
RCT Entities:
BACKGROUND: To compare the effect of two different prostaglandin analogues (Travatan® vs. Xalatan®) on ocular surface parameters. METHODS: This study includes 44 eyes of 44 patients with newly diagnosed primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Patients were randomly divided into two groups and treated with either benzalkonium chloride (BAK)-preserved latanoprost and polyquad-preserved travoprost. Changes in intraocular pressure (IOP) levels and ocular surface parameters including ocular surface disease index (OSDI) questionnaire, tear breakup time (TBUT), ocular surface staining scores, and Schirmer test scores of patients were performed at baseline, 1, 3, 6, and 12 months of treatment and compared. RESULTS: The age, sex ratio, visual acuity, central corneal thickness, and cup/disc ratio were similar between the groups. A decrease in IOP levels (23.3 ± 2.5 to 15.5 ± 2.3), TBUT (5.5 ± 2.3 to 4.1 ± 1.7 s), Schirmer test values (11.3 ± 5.9 to 8.6 ± 4.7 s), and a worsening in OSDI scores (44.6 ± 15.2 to 55.1 ± 13.1) and staining scores (1.7 ± 1.6 to 2.3 ± 1.8) were observed in all patients in the first month of treatment (p < 0.05, for all). No further worsening was detected during the 1-year follow-up. There was no difference between the groups in terms of alterations in IOP levels and ocular surface parameters. CONCLUSION:Travatan® and Xalatan® have a similar effect on IOP levels and ocular surface parameters in patients with POAG and OHT.
Authors: Anthony J Bron; Cintia S de Paiva; Sunil K Chauhan; Stefano Bonini; Eric E Gabison; Sandeep Jain; Erich Knop; Maria Markoulli; Yoko Ogawa; Victor Perez; Yuichi Uchino; Norihiko Yokoi; Driss Zoukhri; David A Sullivan Journal: Ocul Surf Date: 2017-07-20 Impact factor: 5.033
Authors: José Alvaro P Gomes; Dimitri T Azar; Christophe Baudouin; Nathan Efron; Masatoshi Hirayama; Jutta Horwath-Winter; Terry Kim; Jodhbir S Mehta; Elisabeth M Messmer; Jay S Pepose; Virender S Sangwan; Alan L Weiner; Steven E Wilson; James S Wolffsohn Journal: Ocul Surf Date: 2017-07-20 Impact factor: 5.033
Authors: Robert D Fechtner; David G Godfrey; Donald Budenz; Jeanette A Stewart; William C Stewart; Mark C Jasek Journal: Cornea Date: 2010-06 Impact factor: 2.651
Authors: Andrew Camp; Sarah R Wellik; Jonathan H Tzu; William Feuer; Kristopher L Arheart; Ananth Sastry; Anat Galor Journal: Cont Lens Anterior Eye Date: 2015-02-24 Impact factor: 3.077
Authors: Robert J Casson; Glyn Chidlow; John P M Wood; Jonathan G Crowston; Ivan Goldberg Journal: Clin Exp Ophthalmol Date: 2012-04-05 Impact factor: 4.207
Authors: Carol B Toris; Guilin Zhan; Shan Fan; Jaime E Dickerson; Theresa A Landry; Michael V W Bergamini; Carl B Camras Journal: J Glaucoma Date: 2007-03 Impact factor: 2.503
Authors: Raul E Ruiz-Lozano; Jimena Alamillo-Velazquez; Gustavo Ortiz-Morales; Lucas A Garza-Garza; Manuel E Quiroga-Garza; Carlos Alvarez-Guzman; Alejandro Rodriguez-Garcia Journal: Int Ophthalmol Date: 2022-08-13 Impact factor: 2.029